The treatment landscape for multiple myeloma has shifted since European ... reviewed the treatment landscape at the National Comprehensive Cancer Network (NCCN) 2023 Annual Conference.

Sarclisa was added to the National Comprehensive Cancer Network (NCCN) guidelines for non-transplant multiple myeloma candidates as a category 1 (preferred) option alongside VRd and Darzalex plus ...

Cancer patients may have an increased risk of developing second primary malignancies after immune checkpoint inhibitor therapy.

Women and stage 2 multiple myeloma patients report ... experience psychological distress. In 1997, the National Comprehensive Cancer Network developed the “Distress Thermometer” survey ...

What Is Refractory Multiple Myeloma? Multiple myeloma is a cancer that affects a type of white blood cell called a plasma cell, which helps your immune system fight infections. Refractory means ...